Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study
Johan Sundström(Uppsala University), Navdeep Tangri(Seven Oaks General Hospital), Gijs VanPottelbergh, Johan Bodegård, Avraham Karasik(Maccabi Institute for Health Services Research), Manish M. Sood, Marc Vervloet(Amsterdam UMC Location VUmc), Patrick B. Mark(University of Glasgow), Andreas Bollmann(Leipzig Heart Institute), Tiago Taveira‐Gomes(Universidade do Porto), Marcus Thuresson(Statisticon (Sweden)), Levy Jäger(University of Zurich), Manuel Botana(Hospital Universitario Lucus Augusti), Kåre I. Birkeland(University of Oslo)
Cited by 315
Related Papers
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity
|European Heart Journal|2005|1.1k
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
|Kidney International|2017|998
Chronic Kidney Disease and Coronary Artery Disease
|Journal of the American College of Cardiology|2019|716
Tailored Atrial Substrate Modification Based on Low-Voltage Areas in Catheter Ablation of Atrial Fibrillation
|Circulation Arrhythmia and Electrophysiology|2014|561